COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors
© 2021. The Author(s)..
Abnormal glucose and lipid metabolism in COVID-19 patients were recently reported with unclear mechanism. In this study, we retrospectively investigated a cohort of COVID-19 patients without pre-existing metabolic-related diseases, and found new-onset insulin resistance, hyperglycemia, and decreased HDL-C in these patients. Mechanistically, SARS-CoV-2 infection increased the expression of RE1-silencing transcription factor (REST), which modulated the expression of secreted metabolic factors including myeloperoxidase, apelin, and myostatin at the transcriptional level, resulting in the perturbation of glucose and lipid metabolism. Furthermore, several lipids, including (±)5-HETE, (±)12-HETE, propionic acid, and isobutyric acid were identified as the potential biomarkers of COVID-19-induced metabolic dysregulation, especially in insulin resistance. Taken together, our study revealed insulin resistance as the direct cause of hyperglycemia upon COVID-19, and further illustrated the underlying mechanisms, providing potential therapeutic targets for COVID-19-induced metabolic complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 6(2021), 1 vom: 16. Dez., Seite 427 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Xi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 04.01.2022 Date Revised 19.04.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-021-00822-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334526906 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334526906 | ||
| 003 | DE-627 | ||
| 005 | 20231225223903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-021-00822-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334526906 | ||
| 035 | |a (NLM)34916489 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Xi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2022 | ||
| 500 | |a Date Revised 19.04.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Abnormal glucose and lipid metabolism in COVID-19 patients were recently reported with unclear mechanism. In this study, we retrospectively investigated a cohort of COVID-19 patients without pre-existing metabolic-related diseases, and found new-onset insulin resistance, hyperglycemia, and decreased HDL-C in these patients. Mechanistically, SARS-CoV-2 infection increased the expression of RE1-silencing transcription factor (REST), which modulated the expression of secreted metabolic factors including myeloperoxidase, apelin, and myostatin at the transcriptional level, resulting in the perturbation of glucose and lipid metabolism. Furthermore, several lipids, including (±)5-HETE, (±)12-HETE, propionic acid, and isobutyric acid were identified as the potential biomarkers of COVID-19-induced metabolic dysregulation, especially in insulin resistance. Taken together, our study revealed insulin resistance as the direct cause of hyperglycemia upon COVID-19, and further illustrated the underlying mechanisms, providing potential therapeutic targets for COVID-19-induced metabolic complications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Liu, Chenshu |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jiangyun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zilun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Ao |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Meixiu |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Kan |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Dongxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fuchun |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Weiping |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Xinghua |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Zhongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xilong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yueping |e verfasserin |4 aut | |
| 700 | 1 | |a Mo, Xiaoneng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Linghua |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yaling |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yuanyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yanrong |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Huichao |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Baolin |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Wenxin |e verfasserin |4 aut | |
| 700 | 1 | |a He, Ruiying |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiaojiao |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Pengle |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuo, Youguang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Lingzhai |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Fengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wenxue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zefeng |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Zeling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Xiqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Weikang |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Ziming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xinwen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Sifan |e verfasserin |4 aut | |
| 700 | 1 | |a Lei, Chunliang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 6(2021), 1 vom: 16. Dez., Seite 427 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:1 |g day:16 |g month:12 |g pages:427 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-021-00822-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 1 |b 16 |c 12 |h 427 | ||